A study on the effectiveness of Indomethacin in preventing post Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
Among patients undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP), does a single dose of Indomethacin reduce the incidence of Post-ERCP Pancreatitis?
Vinh-An Phan
600 participants
Feb 20, 2013
Interventional
Conditions
Summary
We propose a randomised control study to assess the use of prophylactic Non-steroidal Anti-inflammatory Drugs for the prevention of Post Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis.
Eligibility
Inclusion Criteria1
- All patients undergoing Endoscopic Retrograde Cholangiopancreatography
Exclusion Criteria6
- Those with active pancreatitis
- Renal impairment
- known allergy to non-steroidal anti-inflammatory drugs (including NSAID induced asthma)
- patients with concomitant NSAID therapy (excluding Aspirin)
- patients without a native papilla
- Active peptic ulcer disease
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Indomethacin is a Non-Steroidal Anti-inflammatory Drug (NSAID), which is commonly used to treat fever, headaches, and bone, muscular or joint pain. It works by inhibiting the production of prostaglandins (known to cause such symptoms). It is marketed under several names, including Indocid and Arthrexin. In our study, participants will be given an Indomethacin suppository (dose given rectally) 5 minutes before the commencement of the ERCP. We will then be monitoring our patients for 90 minutes post procedure for symptoms, which would suggest pancreatitis (in particular abdominal pain).
Locations(4)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12613000096752